31 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 3, May/June 2018
AFRICA
161
disease
. Curr Opin HIV AIDS
2010;
5
(6): 511–516.
11. Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction:
the early predictor of atherosclerosis.
Cardiovasc J Afr
2012;
23
(4):
222–231.
12. Sundd P, Pospieszalska MK, Cheung LS, Konstantopoulos K, Ley K.
Biomechanics of leukocyte rolling
. Biorheology
2011;
48
(1): 1–35.
13. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J,
et al
. Arterial inflammation in patients with HIV.
J Am Med Assoc
2012;
308
(4): 379–386.
14. Stein JH, Currier JS, Hsue PY. Arterial disease in patients with human
immunodeficiency virus infection: what has imaging taught us?
J Am
Coll Cardiol Cardiovasc Imaging
2014;
7
(5): 515–525.
15. Tawakol A, Lo J, Zanni M, Marmarelis M, Ihenachor E, MacNabb M,
et
al
. Increased arterial inflammation relates to high-risk coronary plaque
morphology in HIV-infected patients.
J Acquir Immune Defic Syndr
2014;
66
(2): 164–171.
16. Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV,
et al
. Effects of
statin therapy on coronary artery plaque volume and high-risk plaque
morphology in HIV-infected patients with subclinical atherosclerosis: a
randomised, double-blind, placebo-controlled trial.
Lancet HIV
2015;
2
(2): e52–63.
17. Figueroa AL, Takx RA, MacNabb MH, Abdelbaky A, Lavender ZR,
Kaplan RS,
et al.
Relationship between measures of adiposity, arterial
inflammation, and subsequent cardiovascular events.
Circ Cardiovasc
Imaging
2016;
9
(4): e004043.
18. De Pablo-Bernal RS, Ramos R, Genebat M, Cañizares J, Rafii-El-Idrissi
Benhnia M, Muñoz-Fernández MA,
et al
. Phenotype and polyfunc-
tional deregulation involving interleukin 6 (il-6)- and il-10-producing
monocytes in HIV-infected patients receiving combination antiretroviral
therapy differ from those in healthy older individuals.
J Infect Dis
2016;
213
(6): 999–1007.
19. Jalbert E, Crawford TQ, D’Antoni ML, Keating SM, Norris PJ,
BNakamoto BK,
et al
. IL-1-beta enriched monocytes mount massive
IL-6 responses to common inflammatory triggers among chronically
HIV-1 infected adults on stable anti-retroviral therapy at risk for cardio-
vascular disease
. PLoS One
2013;
8
(9): e75500.
20. Bahrami H, Budoff M, Haberlen SA, Rezaeian P, Ketlogetswe K, Tracy
R,
et al
. Inflammatory markers associated with subclinical coronary
artery disease: the Multicenter AIDS Cohort Study
.
J Am Heart Assoc
2016;
5
(6): e003371.
21. Hsu DC, Ma YF, Hur S, Li D, Rupert A, Scherzer R,
et al
. Plasma IL-6
levels are independently associated with atherosclerosis and mortality
in HIV-infected individuals on suppressive antiretroviral therapy.
AIDS
2016;
30
(13): 2065–2074.
22. Borges AH, O’Connor JL, Phillips AN, Neaton JD, Grund B, Neuhaus
J,
et al
. Interleukin 6 Is a stronger predictor of clinical events than high-
sensitivity C-reactive protein or D-dimer during HIV infection
.
J Infect
Dis
2016;
214
(3): 408–416.
23. McDonald B, Moyo S, Gabaitiri L, Gaseitsiwe S, Bussmann H, Koethe
JR,
et al.
Persistently elevated serum interleukin-6 predicts mortality
among adults receiving combination antiretroviral therapy in Botswana:
results from a clinical trial.
AIDS Res Hum Retroviruses
2013;
29
(7):
993–999.
24. Knudsen TB, Ertner G, Petersen J, Møller HJ, Moestrup SK, Eugen-
Olsen J,
et al
. Plasma soluble CD163 level independently predicts all-
cause mortality in HIV-1-infected individuals
. J Infect Dis
2016;
214
(8):
1198–1204.
25. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S,
et al
. Soluble CD163 made by monocyte/macrophages is a novel marker
of HIV activity in early and chronic infection prior to and after anti-
retroviral therapy
.
J Infect Dis
2011;
204
(1): 154–163.
26. Barbour JD, Jalbert EC, Chow DC, Gangcuangco LMA, Norris PJ,
Keating SM,
et al
. Reduced CD14 expression on classical monocytes
and vascular endothelial adhesion markers independently associate
with carotid artery intima media thickness in chronically HIV-1 infected
adults on virologically suppressive anti-retroviral therapy
. Atherosclerosis
2014;
232
(1): 52–58.
27. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER,
et al
. Use of carotid ultrasound to identify subclinical vascular disease
and evaluate cardiovascular disease risk: a consensus statement from
the American Society of Echocardiography Carotid Intima–Media
Thickness Task Force. Endorsed by the Society for Vascular Medicine
.
J
Am Soc Echocardiogr
2008;
21
(2): 93–111; quiz 189–190.
28. Fourie CM, Schutte AE, Smith W, Kruger A, van Rooyen JM.
Endothelial activation and cardiometabolic profiles of treated and never-
treated HIV infected Africans
. Atherosclerosis
2015;
240
(1): 154–160.
29. Graham SM, Rajwans N, Tapia KA, Jaoko W, Estambale BBA, Scott R,
et al
. A prospective study of endothelial activation biomarkers, including
plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating
antiretroviral therapy.
BMC Infect Dis
2013;
13
: 263.
30. Longenecker CT, Funderburg NT, Jiang Y, Debanne S, Storer N,
Labbato DE,
et al
. Markers of inflammation and CD8 T-cell activa-
tion, but not monocyte activation, are associated with subclinical
carotid artery disease in HIV-infected individuals
. HIV Med
2013;
14
(6):
385–390.
31. Hileman CO, Longenecker CT, Carman TL, McComsey GA. C-reactive
protein predicts 96-week carotid intima media thickness progression in
HIV-infected adults naive to antiretroviral therapy
. J Acquir Immune
Defic Syndr
2014;
65
(3): 340–344.
32. Beltran LM, Hernández RM, de Pablo Bernal RS, Morillo JSG, Egido
J, Noval ML,
et al.
Reduced sTWEAK and increased sCD163 levels in
HIV-infected patients: modulation by antiretroviral treatment, HIV repli-
cation and HCV co-infection.
PLoS One
2014;
9
(3): e90541.
33. Grome HN, Barnett L, Hagar CC, Harrison DG, Kalams SA, Koethe
JR. Association of T cell and macrophage activation with arterial vascu-
lar health in HIV.
AIDS Res Hum Retroviruses
2017;
33
(2): 181–186.
34. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U,
et al
. Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90
antiretroviral therapy and virological suppression goals: a population-
based survey.
Lancet HIV
2016;
3
(5): e221–230.